SCHEMBL5545262

SCHEMBL5545262

O=COC(c1ccc(Cl)cc1)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 4/20 0.46
TDO2 P48775 4/20 0.46
IDO2 Q6ZQW0 1/20 0.46
TP53 P04637 1/20 0.39
ALDH1A1 P00352 1/20 0.37
MDM2 Q00987 1/20 0.36
SLC6A2 P23975 3/20 0.35
SLC6A3 Q01959 2/20 0.35
AHR P35869 1/20 0.34
LMNA P02545 2/20 0.34
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
EPHX1 P07099 1/20 0.34
ADORA3 P0DMS8 1/20 0.34
CHRM1 P11229 1/20 0.34
PDE4A P27815 1/20 0.34
EPHX2 P34913 1/20 0.34
ADRA1A P35348 1/20 0.34
OPRM1 P35372 1/20 0.34
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5542504 0.93 IDO1 (0.47) IDO1TDO2IDO2TP53ALDH1A1
SCHEMBL5546049 0.87 IDO1 (0.50) IDO1TDO2TP53SLC6A3LMNA
SCHEMBL5545323 0.81 IDO1 (0.43) IDO1TDO2IDO2SLC6A2SLC6A3
SCHEMBL5537752 0.80 IDO1 (0.58) IDO1TDO2TP53SLC6A2SLC6A3
SCHEMBL5545257 0.76 IDO1 (0.46) IDO1TDO2IDO2TP53MDM2
SCHEMBL5544365 0.73 ACP3 (0.42) IDO1TDO2ALDH1A1MEN1KMT2A
SCHEMBL5545086 0.72 ACP3 (0.46) IDO1TDO2IDO2LMNAMEN1
SCHEMBL5545007 0.71 IDO1 (0.41) IDO1TDO2
SCHEMBL5541135 0.71 CES2 (0.41) ALDH1A1
SCHEMBL5536369 0.69 IDO1 (0.47) IDO1TDO2TP53ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 IDO1 3181/4885TDO2 1351/4885IDO2 2882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.